Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pentetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.46 |
| ▸ | CA4 known ✓ | P22748 | 7/20 | 0.41 |
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.41 |
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL1092340 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL342065 | 0.97 | KDM4E (0.81) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL1478010 | 0.97 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL30903920 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL30179401 | 0.94 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL276109 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL11324791 | 0.94 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL8372011 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL15654929 | 0.94 | KDM4E (0.70) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL29363230 | 0.94 | KDM4E (0.77) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114456671-B | Coating and preparation method and application thereof | 北京国原新技术有限公司 | 2022-12-02 | — | — | CN | claimed |
| EP-2999706-B1 | CRYSTALLINE FORMS OF TRISODIUM ZINK DIETHYLENE TRIAMINE PENTAACETIC ACID | HAMELN PHARMA PLUS GMBH (DE) | 2017-07-19 | — | — | EP | claimed |
| US-9447120-B2 | Crystalline forms of zinc trisodium pentetic acid | HAMELN PHARMA PLUS GMBH (DE) | 2016-09-20 | — | — | US | claimed |
| US-20160130283-A1 | CRYSTALLINE FORMS OF ZINC TRISODIUM PENTETIC ACID | HAMELN PHARMA PLUS GMBH (DE) | 2016-05-12 | — | — | US | claimed |
| EP-4442128-A1 | SMOKELESS TOBACCO POUCH | R. J. Reynolds Tobacco Company (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118527116-B | Modified biomass charcoal-sodium alginate gel and preparation method and application thereof | 中国农业科学院农业环境与可持续发展研究所 | 2024-09-27 | — | — | CN | disclosed |
| CN-118527116-A | Modified biomass charcoal-sodium alginate gel and preparation method and application thereof | 中国农业科学院农业环境与可持续发展研究所 | 2024-08-23 | — | — | CN | disclosed |
| EP-3226700-B1 | SMOKELESS TOBACCO POUCH | REYNOLDS TOBACCO CO R (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240074481-A1 | CAPSULE-CONTAINING POUCHED PRODUCT FOR ORAL USE | REYNOLDS TOBACCO CO R (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2024030085-A1 | A DEVICE FOR CLEANING HEAVY METAL-BOUND MEDIATORS IN BODY FLUIDS AND ORGANS | INNOWAYRG ARASTIRMA GELISTIRME VE DANISMANLIK HIZMETLERI SANAYI VE TICARET ANONIM SIRKETI (TR) | 2024-02-08 | — | — | WO | disclosed |
| US-11832640-B2 | Capsule-containing pouched product for oral use | R.J. REYNOLDS TOBACCO COMPANY (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230312610-A1 | Anti-Microbial Compositions | 5D HEALTH PROTECTION GROUP LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| US-9045474-B2 | Compounds and compositions for mitigating tissue damage and lethality | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-02 | — | — | US | disclosed |
| US-20130231518-A1 | COMPOUNDS AND COMPOSITIONS FOR MITIGATING TISSUE DAMAGE AND LETHALITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2601191-A2 | COMPOUNDS AND COMPOSITIONS FOR MITIGATING TISSUE DAMAGE AND LETHALITY | The Regents of the University of California (US) | 2013-06-12 | — | — | EP | disclosed |
| WO-2012018932-A2 | COMPOUNDS AND COMPOSITIONS FOR MITIGATING TISSUE DAMAGE AND LETHALITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20100316700-A1 | SYSTEMIC ADMINISTRATION OF LIPOSOMAL REDUCED GLUTATHIONE FOR THE DECORPORATION OF RADIOACTIVE MATERIALS AND NON-RADIOACTIVE MERCURY | GUILFORD F TIMOTHY | 2010-12-16 | — | — | US | disclosed |
| EP-1922150-A1 | PROCESS FOR MILLING AND PREPARING POWDERS AND COMPOSITIONS PRODUCED THEREBY | Nanotherapeutics, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080029625-A1 | PROCESS FOR MILLING AND PREPARING POWDERS AND COMPOSITIONS PRODUCED THEREBY | NANOSHIFT, LLC | 2008-02-07 | — | — | US | disclosed |
| WO-2007008480-A1 | PROCESS FOR MILLING AND PREPARING POWDERS AND COMPOSITIONS PRODUCED THEREBY | NANOTHERAPEUTICS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130283-A1 | CRYSTALLINE FORMS OF ZINC TRISODIUM PENTETIC ACID | SLC39A11, SLC30A6, SLC39A3 | ACE 150/4885CA4 203/4885CA2 157/4885 |
| US-20100316700-A1 | SYSTEMIC ADMINISTRATION OF LIPOSOMAL REDUCED GLUTATHIONE FOR THE DECORPORATION OF RADIOACTIVE MATERIALS AND NON-RADIOACTIVE MERCURY | GSS, GPX4, SLC40A1 | ACE 2975/4885CA4 1441/4885CA2 2242/4885 |
| US-20130231518-A1 | COMPOUNDS AND COMPOSITIONS FOR MITIGATING TISSUE DAMAGE AND LETHALITY | CASP3, L3MBTL4, L3MBTL3 | ACE 764/4885CA4 478/4885CA2 1600/4885 |
| US-20230312610-A1 | Anti-Microbial Compositions | LPO, POLR1C, NACA | ACE 1252/4885CA4 3227/4885CA2 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.